Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Hemasphere|October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma AllianceStephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.
Blood Advances|April 9, 2020
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphomaColm Keane, Soi C Law, Clare Gould, et al.
American Journal of Hematology|March 3, 2023
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosingSuzanne O Arulogun, Duncan Brian, Harshita Goradia, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Internal Medicine Journal|July 7, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 updateSean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, et al.
Leukemia|November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's MacroglobulinemiaIrene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
American Journal of Hematology|August 17, 2024
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphomaJay Gunawardana, Soi C Law, Muhammed B Sabdia, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Pageof 9